CDC Independent Valuation - 30 June 2024

Thursday 4th July 2024

The 30 June 2024 independent valuation of Infratil’s investment in CDC shows an increase of A$466 million over the three months since the 31 March 2024 valuation.

Infratil’s 48.25% investment in CDC is now valued at between A$4,159 million to A$4,940 million (with a midpoint of A$4,524 million), up from A$3,783 million to A$4,368 million (with a midpoint of A$4,058 million) at the end of March 2024.

The increase in valuation reflects the updated CDC pipeline disclosed at the announcement of Infratil’s June 2024 equity raising. CDC is currently in advanced negotiations with customers for over 400MW of capacity across multiple sites, expected to come online over the next 4-5 years. As a result, CDC is developing a new Sydney data centre campus at Marsden Park, contributing to an increase in CDC’s future build capacity by 661MW to 1,197MW and total planned capacity of 1,887MW (up from 1,220MW in March 2024). This expanded pipeline demonstrates the favourable market tailwinds for data centres and the strong progress in CDC’s customer discussions. Total operating capacity has increased by 34MW since 31 March 2024, reflecting CDC’s first data centre development in Melbourne (Brooklyn 1) commencing operations.

Region Status Build Capacity (MW), as at 31 March 2024 Build Capacity (MW), as at 30 June 2024

Canberra Operating 117 117

Sydney Operating 123 123

Melbourne Operating - 34

Auckland Operating 28 28

Total Operating Capacity 268 302

Canberra Under Construction 39 39

Sydney Under Construction 158 158

Melbourne Under Construction 151 121

Auckland Under Construction 68 70

Total Under Construction Capacity 416 388

Canberra Future Build 91 90

Sydney Future Build 269 872

Melbourne Future Build 98 157

Australian Expansion Future Build 36 36

Auckland Future Build 42 42

Total Future Build Capacity 536 1,197

Total Capacity 1,220 1,887

The blended cost of equity used in the valuation has increased from 11.25% to 11.50% between March and June 2024. This primarily reflects an increase in gearing as a result of higher forecast debt levels as CDC continues investment in its expanded development pipeline. The increase in gearing is partially offset by a decrease in the asset-specific risk premium, driven by the valuer’s assessment of the status of CDC’s customer discussions and their overall view of CDC’s ability to deliver on its forecast growth. The risk-free rate has remained constant at 3.90%.

From a funding perspective, this valuation reflects the guidance provided as part of Infratil’s June 2024 equity raising, with Infratil’s pro-rata share of equity contributions to CDC at approximately A$600 million over the next two years. This represents an increase of ~A$150 million (on the same pro-rata basis) relative to what was assumed in the March 2024 valuation. CDC intends to continue accessing a range of debt markets to provide further funding for its expanded development pipeline.

Net debt as at 30 June 2024 was A$3,262 million.

CDC’s FY2025 full-year EBITDAF guidance of A$320 million to A$330 million remains unchanged.

Enquiries should be directed to:

Mark Flesher

Investor Relations

mark.flesher@infratil.com

Appendix 1 – Independent Valuation Summary 30 June 2024

Valuation Methodology 31 March 2024 30 June 2024

Primary valuation methodology DCF using FCFE (with a cross check to comparable companies and precedent transactions), surplus and underutilised land at cost

Forecast period 15 years (2039) 15 years (2039)

Enterprise value A$11,118m A$12,723m

Equity value A$8,412m

(IFT share A$4,058m) A$9,376m

(IFT share A$4,524m)

Key Valuation Assumptions

Risk free rate 3.90% 3.90%

Asset beta 0.55 0.55

Cost of equity

(blended rate) reflecting the assessed risk of the spectrum of CDC’s activity, from operating data centres with contracted revenues through to developing projects without contracted revenues. 11.25% 11.50%

Terminal growth rate 2.5% 2.5%

Long term EBITDA margin 85% 85%

Capex

Future capex reflects CDC’s published development pipeline Valuation assumes no development beyond 2031 Valuation assumes no development beyond 2033

CDC Independent Valuation - 30 June 2024

Comments from our readers

No comments yet